CN104093408A - 用于治疗纤维化疾病的pi3k抑制剂 - Google Patents

用于治疗纤维化疾病的pi3k抑制剂 Download PDF

Info

Publication number
CN104093408A
CN104093408A CN201380008089.XA CN201380008089A CN104093408A CN 104093408 A CN104093408 A CN 104093408A CN 201380008089 A CN201380008089 A CN 201380008089A CN 104093408 A CN104093408 A CN 104093408A
Authority
CN
China
Prior art keywords
difluoro
pharmaceutically acceptable
methoxy
pyridazinyl
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380008089.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·F·伍斯特
P·T·卢基
P·J·T·瓦兰斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of CN104093408A publication Critical patent/CN104093408A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201380008089.XA 2012-02-06 2013-02-04 用于治疗纤维化疾病的pi3k抑制剂 Pending CN104093408A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261595293P 2012-02-06 2012-02-06
US61/595,293 2012-02-06
US201261702854P 2012-09-19 2012-09-19
US61/702,854 2012-09-19
PCT/EP2013/052112 WO2013117503A2 (en) 2012-02-06 2013-02-04 Novel use

Publications (1)

Publication Number Publication Date
CN104093408A true CN104093408A (zh) 2014-10-08

Family

ID=47633093

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380008089.XA Pending CN104093408A (zh) 2012-02-06 2013-02-04 用于治疗纤维化疾病的pi3k抑制剂

Country Status (10)

Country Link
US (2) US20150051215A1 (enExample)
EP (1) EP2812002A2 (enExample)
JP (1) JP2015509483A (enExample)
KR (1) KR20140127307A (enExample)
CN (1) CN104093408A (enExample)
AU (1) AU2013218148A1 (enExample)
BR (1) BR112014018106A2 (enExample)
CA (1) CA2861521A1 (enExample)
RU (1) RU2014128387A (enExample)
WO (1) WO2013117503A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018177301A1 (zh) 2017-04-01 2018-10-04 郑州大学 15-亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物及其在制备抗纤维化药物中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
EP3099380B1 (en) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
SG11201808478RA (en) * 2015-07-30 2018-10-30 Univ Monash Fibrotic treatment
JP6419097B2 (ja) * 2016-01-14 2018-11-07 学校法人東京農業大学 ヤマノイモ属植物からのディオスコリンの製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300239A1 (en) * 2007-05-18 2008-12-04 Adams Nicholas D Quinoline derivatives as pi3 kinase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY31137A1 (es) * 2007-06-14 2009-01-05 Smithkline Beecham Corp Derivados de quinazolina como inhibidores de la pi3 quinasa

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080300239A1 (en) * 2007-05-18 2008-12-04 Adams Nicholas D Quinoline derivatives as pi3 kinase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HONG XIA ET AL: "Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis", 《THE JOURNAL OF EXPERIMENTAL MEDICINE》, vol. 205, no. 7, 7 July 2008 (2008-07-07), pages 1659 - 1672 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018177301A1 (zh) 2017-04-01 2018-10-04 郑州大学 15-亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物及其在制备抗纤维化药物中的应用

Also Published As

Publication number Publication date
US20160067247A1 (en) 2016-03-10
RU2014128387A (ru) 2016-03-27
EP2812002A2 (en) 2014-12-17
CA2861521A1 (en) 2013-08-15
WO2013117503A2 (en) 2013-08-15
BR112014018106A2 (pt) 2017-06-27
WO2013117503A3 (en) 2013-10-03
KR20140127307A (ko) 2014-11-03
US20150051215A1 (en) 2015-02-19
AU2013218148A1 (en) 2014-07-24
JP2015509483A (ja) 2015-03-30

Similar Documents

Publication Publication Date Title
US20160067247A1 (en) Novel use
JP6271806B2 (ja) ウイルス静止化合物としての抗炎症剤
KR20220026538A (ko) 코로나바이러스 및 피코르나바이러스 감염 치료용 펩티도모방체
EP3298015B1 (en) Pyrazolopyrimidine derivatives
AU2001248324B2 (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
JP2017165751A (ja) Ｂ型肝炎ウイルス共有結合閉環状ｄｎａ形成の阻害剤およびそれらの使用方法
AU2018205275A1 (en) Methods for the treatment of neurological disorders
US20170173025A1 (en) 1-[2-(AMINOMETHYL)BENZYL]-2-THIOXO-1,2,3,5-TETRAHYDRO-4H-PYRROLO[3,2-d]PYRIMIDIN-4-ONES AS INHIBITORS OF MYELOPEROXIDASE
KR20220097420A (ko) 호흡기 세포융합 바이러스 (rsv) 감염 치료용 벤조디아제핀 유도체
DK2975023T3 (en) Guanidine benzoic acid ester compound
CN109476669A (zh) Lim激酶抑制剂
CN119403551A (zh) Tea结构域家族成员的小分子抑制剂
KR20220127824A (ko) 알파1-항트립신 결핍의 치료를 위한 4-((2-옥소피리딘-1(2h)-일)메틸)벤즈아미드
JP6580597B2 (ja) Ｎａｍｐｔ阻害剤および方法
AU2021363616A9 (en) Modulators of the integrated stress response pathway
US10160756B2 (en) Antiviral compounds and methods using same
PT2376479E (pt) Furancarboxamidas substituídas e respetivas utilizações
JP5569816B2 (ja) イミダゾール誘導体
JP2023505703A (ja) Ｌｐａ受容体２阻害剤としての芳香族アミド誘導体
CN116829548A (zh) 作为c-abl抑制剂的吡唑衍生物
WO2001001981A1 (fr) Antagonistes de recepteur de vegf
KR20250036927A (ko) Irak3의 리간드 지정 분해제로서의 치환된 피라졸릴-피리디닐 화합물
HK40038573B (en) Benzopyrazole compound used as rho kinase inhibitor
JPWO2000059913A1 (ja) 新規チアゾロベンゾイミダゾール誘導体
HK1216246B (en) Guanidinobenzoic acid ester compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141008